Opus Genetics, Inc. (IRD) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Opus Genetics, Inc. (IRD) Earnings Overview
As of June 23, 2026, Opus Genetics, Inc. (IRD) reported trailing twelve-month net income of -$107M, reflecting +62.8% year-over-year growth. The company earned $-0.12 per diluted share over the past four quarters, with a net profit margin of -349.3%.
Looking at the long-term picture, IRD's historical earnings data spans multiple years. The company achieved its highest annual net income of $18M in fiscal 2022.
Opus Genetics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including REPL (-$315M net income), JANX (-$114M net income, -1136.3% margin), KRYS ($225M net income, 52.6% margin), IRD has comparable earnings metrics. Compare IRD vs REPL →
IRD Earnings vs Peers
Earnings metrics vs comparable public companies
IRD Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$50M | +13.8% | -$39M | $-0.80 | -349.3% | -271.9% |
| 2024 | -$58M | -476.1% | -$62M | $-2.15 | -523.4% | -564.7% |
| 2023 | -$10M | -155.8% | -$11M | $-0.46 | -52.4% | -55.5% |
| 2022 | $18M | +131.6% | $18M | $0.87 | 44.9% | 45.7% |
| 2021 | -$57M | -130.3% | -$23M | $-3.82 | -9625.3% | -3854.8% |
| 2020 | -$25M | -299.1% | -$20M | $-5.28 | - | - |
| 2019 | -$6M | - | -$4M | $-0.87 | - | - |
Download Data
Export IRD earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IRD — Frequently Asked Questions
Quick answers to the most common questions about buying IRD stock.
What is IRD earnings per share (EPS)?
IRD trailing twelve-month (TTM) diluted EPS is $-0.12, reflecting +62.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Opus Genetics, Inc.'s net income?
Opus Genetics, Inc. (IRD) trailing twelve-month net income is $-107M as of 2025. Earnings grew +62.8% year-over-year.
Is IRD profitable?
IRD is not currently profitable on a TTM basis, reporting a net loss of $-107M. Net margin is -349.3%. Investors should monitor for a return to profitability.
What is IRD's earnings growth rate?
IRD compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are IRD's profit margins?
Opus Genetics, Inc. net profit margin is -349.3%, operating margin is -271.9%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -449.4%.
Is IRD growing earnings?
Yes, IRD earnings are accelerating — EPS growth of +62.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-107M. Earnings momentum is strengthening.
What was IRD's best earnings year?
Opus Genetics, Inc.'s highest annual net income on record is $18M, achieved in fiscal year 2022. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were IRD's earnings last quarter?
IRD's most recent reported quarter was Q1 2026. Net income was $-66M with diluted EPS of $-0.75. For a full breakdown of all quarters, see the quarterly earnings table on this page.